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The allelic variants of peroxisome proliferator-activated receptor alpha (PPARα) can inﬂuence the risk of coronary artery disease
(CAD) by virtue ofits eﬀect onlipid metabolism.However,the roleofPPARα intronic polymorphismwith CAD hasreceived little
attention. The association of allelic variants G/C at intron 7 of the PPAR-alpha gene with CAD was examined in a hospital-based
Indian population. PPAR genotyping was performed in 110 male patients with CAD and 120 age and ethnically matched healthy
males by PCR ampliﬁcation of the gene followed by restriction digestion. Presence of C allele showed a positive association with
CAD (OR = 2.9; 95% CI [1.65–4.145]; P = .009) and also with dyslipidaemia (OR = 2.95, 95% CI (1.5–4.39); P<. 05). Impaired
lipid metabolism in carriers of the PPARα Intron 7C allele is possibly responsible for the predilection to CAD.
1.Introduction
The peroxisome proliferator-activated receptors (PPARs) are
partofasuperfamily ofligand-activatedtranscriptionfactors
involvedinfattyacidoxidationandlipidmetabolism. PPARα
is expressed in the liver, heart, skeletal muscle, and kidney
and regulates lipid and lipoprotein metabolism. PPARα is
also involved in other biological processes, including the
regulation of inﬂammatory and oxidative pathways [1].
The role of PPARα in cardiovascular disease is an inter-
esting area for research because of its association with fatty
acid oxidation, lipid metabolism, and inﬂammation. In gen-
eral, activation of the PPARα, both by natural and synthetic
ligands, is considered beneﬁcial for cardiovascular health
[1]. In an extensive review, Cresci [2] have suggested the
associationofPPAR-alphaallelicpolymorphismwithcardio-
vascular disorders. There is emerging evidence that variation
i nt h eg e n ee n c o d i n gP P A R α contributes to interindividual
variability in lipid levels and cardiac hypertrophy. Jamshidi
et al. [3]d e m o n s t r a t e dt h a tP P A R α G/C polymorphism
inﬂuences human left ventricular growth in response to
exercise and hypertension. There is only one report on the
association between the PPARα G/C polymorphism and car-
diovascular disease events. Flavell et al. [4] had investigated
theassociationbetweenG toCtransversioninintron7ofthe
PPARα gene and progression of atherosclerosis in a Finnish
population. They found that homozygotes of Intron 7C
had increased risk of ischemic heart disease and C allele
carriers had greater progression of atherosclerosis than did
G allele homozygotes. This observation warrants further
studies and a better understanding of the role of PPARα
gene polymorphism in cardiovascular disease. Therefore,
this study was taken up with the objective of examining
the association of PPAR-alpha Intron 7 G/C polymorphism
(G2528C) with CAD in an Indian population.
2.Methods
2.1. Study Sample. All consecutive male patients admitted to
the cardiology ward of the Institute, with angiographically
conﬁrmedCAD,wereenrolledinthestudy.Exclusioncriteria
were clinical evidence of congenital abnormalities, valvular
disease, chronic renal failure, and malignancies. History
of hypertension, diabetes, and dyslipidaemia was obtained2 ISRN Cardiology
from medical records. Subjects were deﬁned as hypertensive
if their systolic blood pressure was ≥140mmHg, if their
diastolic blood pressure was ≥90mmHg, or if they were
receiving any antihypertensive treatment [5]. Patients with
fasting glucose ≥126mg/dL or receiving antidiabetic drugs
were considered diabetic. Dyslipidaemia was deﬁned as
plasma cholesterol concentration ≥200mg/dL, triglyceride
concentration ≥180mg/dL, or intake of lipid lowering
drugs. Demographic details such as smoking and history of
heart diseases among parents and ﬁrst-degree relatives were
recordedby personal interview. Body weight and height were
measured for calculation of Body Mass Index (BMI)—Body
weight (Kg)/(Height (m))2.U n a ﬀected age-matched healthy
malerelativesofthespousewithoutany ofthecardiovascular
risk factors formed the control for comparison. Relatives
of the spouse were chosen because they were matched
for ethnicity and socioeconomic background. Consent for
inclusion in the study was obtained from the subjects. The
research protocol was approved by the Ethics Committee of
the Institute.
2.2. Genotyping. Two milliliters of blood was collected in
a heparinised tube. Genomic DNA was extracted from the
whole blood with the use of the Gene elute: Blood genomic
DNAkit(Sigma).Genotypingwascarriedoutbypolymerase
chain reaction (PCR) and restriction enzyme digestion.
PPARα genotyping was performed in 25 microlitre reaction
mix containing 5 microlitre 5x GoTaq buﬀer, 200 micromole
of each dNTP, 1.75mmol/L MgCl2, 5pmols of each primer,
and 0.5U GoTaq polymerase. PCR primers used by Jamshidi
et al. [3] were adopted for the study. The primer sequences
are Forward -ACAATCACTCCTTAAATATGGTGG and
Reverse- AAGTAGGGACAGACAGGACCAGTA (Sigma).
PCR ampliﬁcation generated fragments of 266bp. PCR
products were digested with 3U TaqI (Fermentas) for 16
hours at 65◦C and resolved using 1.5% agarose gel elec-
trophoresis to 216bp and 50bp in carriers of the C allele.
2.3. Statistics. Chi-square analysis was carried out to test
whether the distribution of PPAR genotypes was in Hardy-
Weinberg equilibrium. Odds ratio was calculated as a mea-
sure of association of the PPAR alleles with coronary artery
disease. Pearson χ2 test was used as the test of signiﬁcance for
the comparison of genotype and allele frequencies between
patients and control. P<. 05 was considered statistically
signiﬁcant.
3.Results
The study sample included 110 patients and 120 controls.
T h em e a na g eo ft h es a m p l ew a s4 8 .64 ± 11.04 years. As
expected, blood pressure, BMI, and history of smoking and
familial incidence of heart disease were higher in patients
(Table 1). Among the patients, 31.8% were diabetic, 40.9%
had hypertension, and dyslipidaemia was reported in 51.8%.
All patients with dyslipidaemia were on lipid lowering drugs.
Noneofthe commonrisk factors were present in the control.
Table 1: Demographic variables in patients with Coronary artery
disease (CAD) and healthy control.
Control CAD
Sample size 120 110
SBP (mean ±SD) 126.02 ±7.83 152.16± 8.86∗
DBP (mean ±SD) 80.50 ±5.25 98.72 ±5.04∗
BMI 23.69 ±2.80 27.01 ±1.78∗
Smokers (%) 34 55∗
Consanguinity (%) 5 8
Family history of
heart disease (%) 19 29∗
∗P<. 01 compared to control.
Table 2: Distribution of PPARα intron 7C variants in patients with
coronary artery disease (CAD).
n Genotype Allele frequency
GC (%) OR (95% CI) C OR (95% CI)
Control120 6.67 0.03
CAD 110 17.27∗ 2.92 (1.62–4.22) 0.09∗∗ 2.9 (1.65–4.145)
∗P = .012, ∗∗P = .009 versus control.
Table 3: Frequency of C allele in coronary artery disease patients
with knownrisk factors.
Risk factors n C Allele
frequency Odds Ratio (95% CI)
Hypertension 45 0.11 1.5 (0.796 –2.2)
Diabetes 35 0.13 2.28 (1.15–3.41)
Dyslipidaemia 57 0.15∗ 2.95 (1.5–4.39)
∗P<. 05 versus patients with normal lipid proﬁle.
A combination of the above risk factors was seen in 56% of
patients.
3.1. Association of PPARα G/C Polymorphism with CAD.
Genotype distribution was in Hardy-Weinberg equilibrium
in the control sample (χ2 = 0.14, P>. 05) as well as among
patients (χ2 = 0.01, P>. 05). The proportion of individuals
with GC genotype was higher among patients compared to
control (Table 2). There was only one CC homozygote in the
patient sample; hence for statistical analysis it was pooled
with GC. The positive association between GC genotype and
coronary artery disease was highly signiﬁcant. The presence
of C allele appears to enhance the risk for development of
CAD (Table 2). The frequency of C allele shows a threefold
increase in patients compared to healthy control.
3.2. Association of PPARα G/C Polymorphism with Risk Fac-
tors for CAD. Analysis of the relative risk associated with the
presenceofCalleleinpatientswithandwithoutthecommon
risk factors for CAD showed that C allele signiﬁcantly
enhances the risk for dyslipidaemia (Table 3).ISRN Cardiology 3
4.Discussion
Risk factors commonly associated with CAD were seen in
patients (Table 1). A signiﬁcant association was observed
between coronary artery disease and PPARα genotypes
(Table 2). The risk for CAD was signiﬁcantly enhanced in
the presence of PPARα C allele. The allele also showed
a positive association with dyslipidaemia (Table 3). Perox-
isome proliferator-activated receptor alpha (PPARα)r e g u -
lates genes involved in lipid metabolism, homeostasis and
inﬂammation, inresponse tofattyacids,andﬁbrates,making
it a candidate gene for risk of dyslipidaemia, atherosclerosis,
and coronary artery disease. Various polymorphic markers
that act as candidate genes are related to lipoprotein
metabolism and accounts for variations in the level of total
serum cholesterol and LDL [6–8]. Though the mutation
(G→C) in Intron 7 of the PPARα gene is in the noncoding
region, studies have indicated its potential biological impor-
tance. Due to its location in the intron, the variant itself may
not be functional, but it may be in allelic association with a
functional variant in a promoter or enhancer element of the
PPARα gene that results in reduced PPARα gene expression
[3]. Intron 1C and intron 7C-alleles mark a haplotype
with reduced PPARα gene expression [9]. Earlier studies
on the association of PPARα Intron 7C polymorphism
with dyslipidaemia in diabetic subjects have shown that
v a r i a t i o ni nt h eP P A R α gene inﬂuences total cholesterol,
LDL-cholesterol (LDL-C), and HDL-cholesterol (HDL-C)in
diabetic patients [10, 11] and that the C allele is associated
with increased total cholesterol and LDL cholesterol [12].
Fibrates are used in the treatment of dyslipidaemia and
cause a reduction in plasma triglycerides. Clinical trials have
shown that ﬁbrates reduce the progression of atherosclerosis
[13] and the incidence of CAD [14, 15]. Reduced response
to ﬁbrate therapy has been reported in individuals with
the C allele [11]. Genetically determined reduced PPARα
level associated with the presence of C allele may be the
determining factor for impaired lipid metabolism, which in
turn enhances the risk of CAD.
5.Conclusion
The study has demonstrated that PPARα allelic variants
inﬂuence the predisposition for CAD in human subjects,
probably mediated by modulation of the lipid proﬁle.
Variations in the human PPARα gene may be one of the con-
tributory factors in the multifactorial etiology of CAD with
carriersoftheCallelehavingapredilectiontothediseasedue
to raised serum cholesterol. More extensive epidemiological
andgeneticstudiesareneededtounderstandtherelationship
between the G/C polymorphism in the PPARα gene and
serum lipid levels. It is also envisaged that studies will be
carried out in other populations to establish the power of
theassociation andalsounderstandthecauseforthereduced
response of C allele carriers to ﬁbrate therapy.
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